Maintenance Therapy for Candida Glabrata After Boric Acid Induction
For a 65-year-old woman with Candida glabrata vaginitis who has completed boric acid induction therapy, initiate maintenance with intravaginal nystatin suppositories 100,000 units daily, as this is the only maintenance regimen specifically recommended for recurrent non-albicans species in the guidelines 1.
Clinical Context and Reasoning
C. glabrata represents a particularly challenging organism because it is inherently less susceptible to azole antifungals compared to C. albicans 1. The 2016 IDSA guidelines address acute treatment of C. glabrata but do not provide specific maintenance recommendations for this species 2. However, the older but still relevant 2002 CDC guidelines explicitly state that "if non-albicans VVC continues to recur, a maintenance regimen of 100,000 units of nystatin delivered daily via vaginal suppositories has been successful" 1.
Maintenance Regimen Details
- Agent: Nystatin vaginal suppositories
- Dose: 100,000 units daily
- Duration: Continue for 6 months 1
- Timing: Begin immediately after completing the 14-day boric acid induction course
Why Not Standard Azole Maintenance?
The typical maintenance regimens recommended for recurrent vulvovaginal candidiasis (fluconazole 150 mg weekly, clotrimazole 500 mg weekly, ketoconazole 100 mg daily, or itraconazole) are designed primarily for C. albicans 1. These azole-based regimens are "not as effective against these species as against C. albicans" 1. The 2016 IDSA guidelines note that C. glabrata is "unresponsive to oral azoles" 2, making standard fluconazole maintenance inappropriate.
Alternative Considerations
If Nystatin Maintenance Fails or Is Not Tolerated:
Intermittent boric acid: While not explicitly recommended in guidelines for maintenance, expert consensus suggests twice-weekly dosing of boric acid (600 mg) can be considered for maintenance in recurrent non-albicans infections 3. This approach has clinical support from tertiary care centers 4.
Episodic treatment: Some women may require episodic full-course boric acid treatment (600 mg daily for 14 days) at the first sign of recurrence rather than continuous suppression 3.
Critical Pitfalls to Avoid
Do not use fluconazole maintenance: This is the most common error. While fluconazole 150 mg weekly is first-line for recurrent C. albicans 2, it is ineffective for C. glabrata maintenance.
Do not stop after acute treatment: Without maintenance therapy, 30-40% of women experience recurrence once treatment is discontinued 1. For C. glabrata specifically, recurrence rates are likely higher given the organism's inherent resistance patterns.
Monitor for recurrence: Even with maintenance therapy, approximately 14% of patients may experience mycological recurrence within 3 months 4. If symptoms recur, obtain repeat cultures to confirm the organism and assess for potential resistance.
Duration and Follow-up
Continue nystatin maintenance for 6 months as recommended for all maintenance regimens 1. After discontinuation, counsel the patient that recurrence remains possible and she should return promptly if symptoms develop. Consider longer-term or intermittent suppressive therapy if recurrence occurs after completing the 6-month course.
Safety Considerations
Nystatin has an excellent safety profile with minimal systemic absorption and local side effects 1. Unlike ketoconazole (which requires hepatotoxicity monitoring at 1 in 10,000-15,000 exposures) 1, nystatin does not require laboratory monitoring during the 6-month maintenance period.